Rosiglitazone - Continued uncertainty about safety

被引:37
作者
Drazen, Jeffrey M.
Morrissey, Stephen
Curfman, Gregory D.
机构
关键词
D O I
10.1056/NEJMe078118
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:63 / 64
页数:2
相关论文
共 5 条
[1]   Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis [J].
Home, Philip D. ;
Pocock, Stuart J. ;
Beck-Nielsen, Henning ;
Gomis, Ramon ;
Hanefeld, Markolf ;
Jones, Nigel P. ;
Komajda, Michel ;
McMurray, John J. V. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) :28-38
[2]   Rosiglitazone and cardiotoxicity - Weighing the evidence [J].
Nathan, David M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) :64-66
[3]   Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (vol 356, pg 2457, 2007) [J].
Nissen, Steven E. ;
Wolski, Kathy .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) :2457-2471
[4]   The record on rosiglitazone and the risk of myocardial infarction [J].
Psaty, Bruce M. ;
Furberg, Curt D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) :67-69
[5]   Rosiglitazone and cardiovascular risk [J].
Psaty, Bruce M. ;
Furberg, Curt D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) :2522-2524